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The parasite Plasmodium vivax is the most widely distributed cause of recurring malaria.
N-Myristoyltransferase (NMT), an enzyme that catalyses the covalent attachment of myristate to the
N-terminal glycine of substrate proteins, has been described as a potential target for the treatment of this
disease. Herein, we report the synthesis and the structure-guided optimization of a series of quinolines
with balanced activity against both Plasmodium vivax and Plasmodium falciparum N-myristoyltransferase
(NMT).
Introduction
N-Myristoyltransferase (NMT, EC 2.3.1.97) catalyses the trans-
fer of the fatty acid chain C14:0 from myristoyl coenzyme A
(MyrCoA) to the N-terminal glycine residue of substrate pro-
teins.1 This co- and post-translational modification is ubiqui-
tous in eukaryotic organisms and plays a central role in a vari-
ety of cellular processes such as the addressing and reversible
anchoring of proteins to membranes.2,3 The N-terminal
myristate chain can also participate in the stabilization of the
tertiary structure of proteins and form part of recognition ele-
ments that establish protein–protein interactions.4,5 Due to
the essential functions of myristoylation, the modulation of
NMT activity has emerged as an attractive strategy in the
treatment of various pathologies. In particular, NMT has been
validated as a pharmacological target in fungal infections,6 in
a range of parasitic diseases caused by Trypanosoma,7 Leish-
mania8 and Plasmodium9–11 protozoa and filarial nematodes,12
and as a potential target for the treatment of cancer.13
The first reported NMT inhibitors were obtained through
rational design strategies, by mimicking the structure of pep-
tide substrates,14,15 or by designing non-hydrolysable MyrCoA
analogues.16,17
Later, novel families of NMT inhibitors were identified by
high throughput screening (HTS) efforts.7,18–20 A selection of dif-
ferent chemotypes are under active development against
NMT for numerous indications (Fig. S1‡), and an NMT inhib-
itor has recently entered the Medicines for Malaria Venture
(MMV) development pipeline for the treatment of the lethal
form of malaria caused by Plasmodium falciparum. We
reported in 2012 the discovery of a Plasmodium vivax NMT
(PvNMT) inhibitor based on a quinoline scaffold.21 P. vivax is
the most frequent parasite responsible for the recurring form
of malaria, whose transmission and infection occur through
the bite of Anopheles mosquitos.22 Vivax malaria strongly im-
pacts the quality of life of infected patients who experience
cyclical fever and weakness episodes and represents a severe
burden in endemic countries, due to cost of treatment and
loss of productivity.23
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Fig. 1 Structure of the optimized molecule 1. clogP was determined
with ChemAxon, which can be obtained from http://www.chemaxon.
com/. LE: ligand efficiency, LE = [−logĲKi)](1.374)/(no. of heavy
atoms).24 LipE: lipophilic efficiency, LipE = −log(Ki) − clogP.24 LELP :
ligand efficiency dependent lipophilicity, LELP = clogP/LE.25 Here, we
report how our attempts to improve the potency of this series of
compounds through a structure-guided strategy led to the identifica-
tion of nanomolar inhibitors of N-myristoyltransferase, active against
both PvNMT and PfNMT.
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Our initial work on the quinoline series resulted in the
elucidation of the crystal structure of a hit compound in com-
plex with PvNMT and the identification of an optimized mol-
ecule, ethyl 4-((2-cyanoethyl)thio)-6-methoxyquinoline-3-car-
boxylate 1, displaying micromolar inhibitory potency against
PvNMT, some selectivity versus the human NMT isoforms
and reasonable physico-chemical properties (Fig. 1). Unfortu-
nately, these compounds showed no activity against the
N-myristoyltransferase of Plasmodium falciparum, the species
causing the most virulent and deadly form of the disease.
Results and discussion
Crystal structure of lead compound 1 in complex with
Plasmodium vivax NMT
First, compound 1 was co-crystallized with PvNMT and S-(2-
oxo)pentadecyl-coenzyme A, a non-hydrolysable myristoyl-co-
enzyme A analogue (Fig. 2),26 and the structure of the
resulting ternary complex was solved by X-ray crystallography.
Overall, 1 adopts a binding mode similar to the original hit
compound, 3-butyl-4-((2-cyanoethyl)thio)-6-methoxy-2-methyl-
quinoline (MRT00057965), which we identified in 2012 by
high throughput screening.21 The quinoline fits into a hydro-
phobic pocket, where it establishes parallel-displaced π–π
stacking interactions with the adjacent side-chains of Phe103
and Phe105. The binding of the quinoline ring is reinforced
by the establishment of an H-bond between its nitrogen and
the hydroxyl function of Ser319. Additionally, the nitrile func-
tion of the 2-cyanoethylthioether chain appears to interact
with the imidazole ring of His213 (distance ∼3.0 Å). The li-
gand is modelled bound to the protein at half maximal occu-
pancy due to the low affinity of binding. This is mirrored in
the two orientations of residues His213 and Tyr211, corre-
sponding to the bound and free forms (Fig. 2). Interestingly,
the ester function, introduced to improve the solubility and
log P of the hit compound, also establishes polar interactions
with PvNMT, through water-mediated H-bonds.
Based on the above structure, the optimization of the 3-,
4- and 6-positions of the quinoline ring was undertaken.
Optimization of the substituent in position 4 of the
quinoline ring
It is well known that 2-cyanoethylthioethers can be cleaved in
the presence of weak bases such as ammonia through a
retro-Michael reaction.27 Although 1 was fully stable in the
phosphate buffered solutions used for enzymatic assay, some
degradation was observed during its chemical synthesis,
suggesting it may represent a hurdle in the future develop-
ment of this series of compounds. Additionally, structural
data indicate that the H-bond formed between the nitrile and
His213 may not be critical for the binding of the inhibitor.
This prompted us to investigate whether the
2-cyanoethylthioether could be advantageously replaced by a
more stable substituent in the 4-position of the quinoline
ring.
First, the linear alkyl isostere 5, with an n-propyl chain in
place of the 2-cyanoethyl, was synthesized. In this series of
molecules, the original 6-methoxy group present in the opti-
mized hit 1 was replaced by a benzyloxy. Indeed, the
6-benzyloxy derivative 4, initially prepared as a synthetic
intermediate to explore the role of the 6-position, was found
to provide an 8-fold improvement in activity compared to the
original methoxy compound, probably due to the establish-
ment of edge-to-face π–π interactions with the side chains of
residues Phe105 and Tyr211 (Table 1). The intermediate ethyl
6-(benzyloxy)-4-hydroxyquinoline-3-carboxylate 2 was obtained
through the thermal condensation and cyclization of
6-benzyloxyaniline and ethyl ethoxymethylenemalonate, and
subsequently transformed into its 4-chloro derivative 3 by
treatment with POCl3 (Scheme 1).
28 Finally, nucleophilic aro-
matic substitution with thiols or sodium thiolates provided
the 4-thioalkyl derivatives 4–8.
The inhibitory potency of 4–8 was assessed using a
fluorogenic enzymatic assay for PvNMT activity.21 Com-
pounds were also tested on PfNMT, the enzyme present
in P. falciparum,29 and on the human isoforms HsNMT1
and HsNMT2.30 Replacing the 2-cyanoethyl thioether with
an n-propyl thioether (compound 5) had a limited impact
on PvNMT activity, confirming that the nitrile function is
not required for high affinity binding to the enzyme.
Interestingly, this modification was also associated with a
>10-fold improvement in activity versus PfNMT. Indeed,
while the original hit compound and compound 4 were
totally inactive on PfNMT up to 100 μM, 5 displayed a Ki
of 1.1 μM, similar to the value measured with PvNMT.
These differences in terms of binding affinity between
PvNMT and PfNMT, two enzymes that share 80% identity,
are difficult to rationalize. The only residue in the
inhibitor-binding pocket that differs between these NMTs
is Tyr334 (Pv numbering), which is replaced by a
Fig. 2 Structure of quinoline 1 in a ternary complex with P. vivax NMT
and S-(2-oxo)pentadecylCoA (NHM) (PDB accession code: 5G1Z). View
of 1 in chain A of PvNMT in cylinder format and colored by atom:
carbon (green), oxygen (red), nitrogen (blue), sulphur (yellow). The side
chains of residues located within 4 Å of 1 are displayed as cylinders
and labelled. Water molecules are shown as red spheres. Polar
interactions with PvNMT are represented as dashed lines. Y211 and
H213 are shown in two alternate conformations. For a stereoview, see
Fig. S2.‡
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phenylalanine in PfNMT. Based on X-ray data, this residue
does not establish polar interactions with the nitrile func-
tion of the inhibitor. Therefore, how such a minor modifi-
cation causes significant changes in binding affinity re-
mains to be defined. Unfortunately, despite substantial
crystallisation efforts, no X-ray structure of PfNMT alone,
or in complex with inhibitors, has been solved so far.
Subsequent modification of the length and nature of the
thioether chain allowed us to identify the ethylthioether de-
rivative 7, as the compound having the best potency against
both PvNMT and PfNMT (Table 1).
The X-ray structure of the complex between 1 and
PvNMT shows that a cluster of water molecules surrounds
the sulfur atom of the thioether chain. We attempted to
establish polar contacts with these water molecules
through the synthesis of the sulfoxide and sulfone deriva-
tives 9 and 10 respectively, which were obtained by
mCPBA-mediated oxidation of 7 at −78 °C and 0 °C re-
spectively (Scheme 2). Unfortunately, both appeared to be
less active than the original thioether 7. At this stage, it
is difficult to determine whether this reduced activity is
due to unfavourable steric clashes/displacement of water
molecules or if it originates from the electron-withdrawing
effects of the sulfone and sulfoxide on the quinoline ring,
which may reduce the strength of the H-bond between
the quinoline nitrogen and Ser319 of PvNMT.
It is worth noting that, although 9 and 10 were less active
than the corresponding alkyl analogue, their LipE values
(based on PvNMT data) were significantly higher due to their
enhanced hydrophilicity. However, the ethyl thioether was
Table 1 Structure and biochemical activity of compounds 4–19 on PvNMT, PfNMT and HsNMTs
Entry
Ki
app (μM)a
clogPb LipEcR3 R4 R6 PvNMT PfNMT HsNMT1 HsNMT2
1 COOEt SCH2CH2CN Me 4.74 ± 0.24 (ref. 21) >100 19.43 ± 0.86 (ref. 21) >100 (ref. 21) 2.63 2.69
4 COOEt SCH2CH2CN Bn 0.55 ± 0.06 >10 >10 n.d. 4.36 1.90
5 COOEt SCH2CH2CH3 Bn 2.08 ± 0.14 1.10 ± 0.08 3.36 ± 0.37 >10 5.46 0.22
6 COOEt SCHĲCH3)2 Bn 2.51 ± 0.16 1.99 ± 0.30 4.84 ± 0.64 >10 5.25 0.35
7 COOEt SCH2CH3 Bn 0.44 ± 0.05 0.67 ± 0.04 1.56 ± 0.22 4.23 ± 0.53 4.94 1.42
8 COOEt SCH3 Bn 4.14 ± 0.41 5.90 ± 0.60 n.d. n.d. 4.69 0.69
9 COOEt SOCH2CH3 Bn 1.75 ± 0.12 5.65 ± 1.24 3.60 ± 0.30 >10 3.30 2.46
10 COOEt SO2CH2CH3 Bn 1.78 ± 0.47 >10 >10 >10 3.41 2.34
11 CH2OH SCH2CH3 Bn 4.19 ± 0.55 >10 >10 >10 3.81 1.57
12 CH2OCH2CH3 SCH2CH3 Bn 2.92 ± 0.15 2.69 ± 0.51 >10 >10 4.81 0.72
13 CO–NHCH2CH3 SCH2CH3 Bn 0.34 ± 0.05 0.96 ± 0.11 1.05 ± 0.115 >10 4.01 2.46
14 CO–NĲCH2CH3)2 SCH2CH3 Bn 0.41 ± 0.06 0.94 ± 0.09 1.02 ± 0.13 3.53 ± 0.40 4.59 1.80
15 CO-N-pyrrolidine SCH2CH3 Bn 0.96 ± 0.13 1.52 ± 0.29 1.36 ± 0.21 >10 4.28 1.74
16d CO–NH–Ph SCH2CH3 Bn n.d. n.d. n.d. n.d. 5.67
17d CO–NH-2-thiazole SCH2CH3 Bn n.d. n.d. n.d. n.d. 5.01
18 CO–NHCH2CH2OH SCH2CH3 Bn 2.84 ± 0.38 8.00 ± 3.98 >10 >10 3.19 2.36
19 CO-N-morpholine SCH2CH3 Bn 0.20 ± 0.02 0.33 ± 0.02 0.10 ± 0.01 0.59 ± 0.05 3.66 3.03
a Apparent Ki values of tested compounds on the enzymatic activity of recombinant P. vivax NMT, P. falciparum NMT and H. sapiens NMT
isoforms 1 and 2. Each Ki is the mean ± SD from duplicates. n.d. : not determined.
b clogP were determined with ChemAxon. c LipE: lipophilic
efficiency, LipE = −logĲKi) − clogP. d No biological data available because of the limited solubility of the compounds in assay buffer.
Scheme 1 Synthetic pathway to compounds 2–8. Reagents and conditions: (i) 140 °C, 1 h; (ii) Ph2O, 240 °C, 2 h; (iii) POCl3, 110 °C, 20 min; (iv)
R-SH or R-SNa, K2CO3, THF or DMF, RT, 1.5–24 h.
Scheme 2 Syntheses of sulfoxide and sulfone derivatives 9 and 10.
Reagents and conditions: (i) m-CPBA, DCM, −78 °C, 4 h; (ii) m-CPBA,
DCM, 0 °C, 2.5 h.
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selected as the preferred substituent for the rest of the study
because of its better synthetic tractability.
Replacement of the ethyl ester group by amides
The original hit compound, MRT00057965, possessed an
n-butyl chain in position 3 of the quinoline ring. In our previ-
ous study,21 this group was replaced by an ethyl ester in or-
der to reduce the lipophilicity of the compound. While this
modification succeeded in improving the hydrophilicity of
the quinoline without significantly impacting the affinity of
the molecule for PvNMT, it represents a potential liability
with respect to hydrolysis in vivo. In an attempt to identify
more suitable substituents, the ester 7 was reduced to form
the alcohol 11, which was subsequently alkylated to provide
the ethyl ether derivative 12 (Scheme 3). Both compounds
showed a 6- to 10-fold reduction in inhibitory activity. Subse-
quently, the ester was replaced by an amide. In order to allow
direct comparison with the ester series, the ethyl amide 13
was synthesized initially, from compound 7 according to
Weinreb's procedure (Scheme 3).31 Encouragingly, 13 showed
the same inhibitory profile as 7, with a Ki of 0.34 μM and
0.96 μM on PvNMT and PfNMT respectively, and a 3-fold and
30-fold selectivity versus HsNMT1 and HsNMT2 respectively.
Superposition of the three quinoline–PvNMT complexes
present in the asymmetric unit of the crystal shows that the
ethyl ester group is flexible and able to adopt different con-
formations in a relatively large pocket, suggesting that the
ethyl chain is suboptimal and that the enzyme may tolerate
larger substituents. This hypothesis was confirmed through
the synthesis of the N,N-diethylamide 14 and the
N-pyrrolidine amide derivative 15 which showed similar levels
of potency as the N-ethylamide 13 across the different en-
zymes. Substitution of the carboxamide with small aromatic
rings (phenyl, 16, or 2-thiazole 17), which could interact with
nearby residues Phe226 and His213, led to the formation of
poorly soluble compounds that could not be evaluated. Fi-
nally, in order to decrease the lipophilicity of the series, and
potentially establish novel electrostatic interactions with the
enzyme, amides substituted with polar functions were synthe-
sized. While the 2-hydroxyethylamide derivative 18 displayed
a significant loss of affinity, the N-morpholine derivative 19
showed an improved potency, as well as a significantly re-
duced clogP.
A ternary crystal structure of 19 in complex with
Leishmania major NMT (LmNMT) and NHM was obtained
(Fig. 3).7,32 LmNMT and PvNMT share 39% sequence identity
and have been used interchangeably for structural biology
studies, with LmNMT offering the more robust platform for
rapid crystallography. As before, the ethyl thioether chain in
position 4 seems to stack against the phenol group of Tyr217
(Tyr211 in PvNMT) and the position of histidine side chain
continues to adopt two orientations. The main difference
with compound 1 arises from the (N-morpholine)carboxamide
group. The orientation of the amide undergoes a 160° twist
compared to the initial orientation of the ester, allowing the
carbonyl to H-bond with Asn376 and via a water molecule
with Tyr345 (Fig. 3). This change is associated with the full
rotation of Phe232 (Phe226 in PvNMT) to accommodate the
presence of the morpholine ring (Fig. S3‡). It remains to be
determined if these changes are specific to compound 19 or
if they occur with all amide derivatives.
Investigation of the substituent in position 6 of the quinoline
ring
Finally, the role of the substituent located on position 6 of
the quinoline ring was explored. The benzyloxy-present in all
the above compounds sits at the top of a narrow cavity, which
leads to the catalytic C-terminal leucine of
N-myristoyltransferase (Fig. 4). Virtually all of the known fam-
ilies of NMT inhibitors interact with the C-terminal residue,
which is a leucine in fungi, Plasmodium and Leishmania but
is a valine in T. brucei and a glutamine in human NMTs. This
interaction is usually formed by an amino group in the inhib-
itor that establishes a strong ionic bond with the C-terminal
Scheme 3 Syntheses of alcohol, ether and amide derivatives 11–19.
Reagents and conditions: (i) LiAlH4, THF, 0 °C, 1 h; (ii) tBuOK, DMSO,
RT then EtI, 60 °C, 1 h; (iii) AlMe3, amine, toluene, −15 °C then 7, RT,
24 h.
Fig. 3 Structure of quinoline 19 in a ternary complex with LmNMT
and MyrCoA (PDB accession code: 5G20). 19 is shown in cylinder
format and colored by atom: carbon (green), oxygen (red), nitrogen
(blue) and sulphur (yellow). A transparent LmNMT surface is shown in
grey. The side chains of selected LmNMT residues located within 4 Å
of 19 are displayed as grey sticks, and labeled. Water molecules are
shown as red spheres. Polar interactions with LmNMT and solvent are
represented as black dashed lines. For a stereo view, see Fig. S2.‡
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NMT carboxylate.7,9,18,33 However, inhibitors containing imid-
azoles34 or neutral functions35 have also been reported to es-
tablish stabilizing interactions with the C-terminus.
With the objective of further increasing the inhibitory po-
tency of the quinoline series, novel molecules were designed,
in which the 6-benzyloxy moiety was replaced by longer sub-
stituents elaborating an amine group at their extremity. By
analogy with DDD85846, the benzyloxy was first replaced by a
(6-(piperazin-1-yl)pyridin-3-yl)methoxy group (Fig. 4).
Compound 21 was prepared from 7 in three steps:
6-hydroxyquinoline intermediate 20 was first formed under
acidic conditions, and was subsequently condensed with
(6-(4-Boc-piperazin-1-yl)pyridin-3-yl)methanol by a Mitsunobu
reaction (Scheme 4). Deprotection of the piperazine afforded
21, with an overall yield after purification of 18%. A similar
strategy was employed to synthesize the derivatives 22–25, in
which the piperazine was replaced with alternative cyclic or
linear diamines (Table 2). These modifications were intro-
duced to identify the most suitable linker and to take into ac-
count potential differences between LmNMT and the
intended target, PvNMT.
Compared to the initial benzyloxy 7, the 4-piperazine-
pyridin-3-yl derivative 21 showed a dramatic improvement in
potency against PvNMT (>10-fold, Ki = 38 nM), and a similar,
while more limited, effect on PfNMT (Ki = 242 nM). This in-
crease in potency was also associated with a loss of selectivity
versus HsNMT1 and HsNMT2. Replacing the piperazine with
a 4-amino-piperazine, a pyrrolidine, or ethylenediamine did
not improve activity against PvNMT or PfNMT. The most
promising results were obtained with the 1,3-propanediamine
derivative 25, which inhibited PvNMT with a Ki of 18 nM.
Crystal structures were determined of 26, in complex with
first PvNMT to explore the basis of potency, and then with
LmNMT, to allow comparison of its binding mode with that
of 19 (Fig. 4, S4, S5 & S6‡). As expected, an ionic interaction
is observed between the piperazine and the C-terminal leu-
cine. This complex is further stabilized by direct and water-
mediated H-bonds of the piperazine with Thr197 and
Asn161. The pyridine ring also establishes a stabilizing polar
interaction with the phenol of Tyr211. The structure of 26
bound to LmNMT (PDB code 5G21) is closely superimposable
but shows a slightly different orientation of Tyr211, possibly
due to multiple orientations of the nitrile tail (Fig. S4‡). It is
worth noting that the quinoline plane of compound 26
adopts a slightly tilted orientation compared to the one occu-
pied by 19 in LmNMT (Fig. S5 & S6‡). We assume that this
potentially unfavourable change is related to an ionic interac-
tion with LmNMT, which constrains the molecule to reduce
Fig. 4 (Left) View of 19 (green carbons) in LmNMT in cylinder format. The surface of LmNMT is shown in grey. 19 is superimposed with
DDD85646 (2,6-dichloro-4-(2-piperazin-1-ylpyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide; magenta carbons), a known
NMT inhibitor. The surface above the C-terminal leucine of NMT is colored in red. (Right) Crystal structure of 26 (cyan carbons) in complex with
PvNMT and non-hydrolizable MyrCoA (pdb accession code: 5G22). Selected side chains of PvNMT are shown in cylinder (format) and labeled
according to PvNMT numbering. Dashed lines indicate electrostatic/H-bond interactions. For further views of 26 in complex with PvNMT and
LmNMT, see Fig. S4, S5 & S6.‡
Scheme 4 Synthesis of compound 21. Reagents and conditions: (i) methanesulfonic acid 10% (v/v) in TFA, 60 °C, 4 h; (ii) (6-(4-Boc-piperazin-1-
yl)pyridin-3-yl)methanol, DEAD, PPh3, THF, RT, 16 h; (iii) TFA 20% in DCM, RT, 40 min.
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the distance between the piperazine nitrogen and Leu421 car-
boxylate. This may explain the higher potency of the more
flexible 1,3-propanediamine derivative 25.
Conclusion
Starting from the crystal structure of compound 1 in PvNMT,
the positions 3-, 4- and 6-substituents of the quinoline ring
were sequentially modified, with the aim of improving chemi-
cal stability, solubility and affinity of this series of com-
pounds for N-myristoyltransferases. Interestingly, while the
primary objective of this work was to increase the inhibitory
potency of the quinoline series for PvNMT, we observed that
the substitution of the 2-cyanoethythioether moiety by an al-
kyl thioether resulted in a significant improvement in the ac-
tivity towards Plasmodium falciparum NMT, affording novel
lead compounds with balanced activities against both PvNMT
and PfNMT. Moreover, controlling the lipophilicity as part of
the optimization process allowed us to identify novels inhibi-
tors with significantly improved lipophilic efficiency.
The low selectivity over host NMT may limit the potential
to progress this series to lead optimisation.36 However, we re-
cently reported that ligands that induce conformational
changes in Tyr211 of PvNMT were selective for Plasmodium
NMTs over human NMT,9 and further investigation of the
4-position of the quinoline, which is in contact with Tyr211,
may be a fruitful area for future exploration.
Finally, we expect that the crystal structures obtained as
part of this work, along with information on the quinoline
binding mode, will support the development of even more
potent N-myristoyltransferase inhibitors, based on a quinoline
core alone or hybridized with other series of inhibitors
targeting NMT.18,35
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